Bipolar disorder Flashcards
Point prevalence of bipolar disorder
1.5%
Average age of onset of bipolar disorder
18-20
Increased risk of suicide among people with bipolar disorder compared to the general population
15-18x higher
Lifetime prevalence of bipolar I
1.0%
Lifetime prevalence of bipolar II
1.1%
Lifetime prevalence of subsyndromal bipolar spectrum
2.4%
Differences between bipolar I and bipolar II
Bipolar I has one or more manic or mixed episodes and typically has recurrent depressive episodes
Bipolar II must have at least one hypomanic episode and at least one depressive episode
Description of bipolar III
Recurrent depression with hypomania occurring only with antidepressants or other treatment
Percentage of patients with bipolar disorder who were previously misdiagnosed as having depression
40%
Stability of a bipolar diagnosis
70-91%
Average length of time to recover from a treated episode of mania
4-5 weeks
Percentage of patients with bipolar who show predominantly either depression or mania
56%
Of patients with bipolar who show polarity in their symtpoms, percentage who show mainly depressive symptoms
60%
Of patients with bipolar who show polarity in their symtpoms, percentage who show mainly manic symptoms
40%
Percentage of patients with bipolar who complete suicide
10-19%
Percentage of patients with bipolar who attempt suicide
25-35%
Percentage of suicide attempts in patients with bipolar which occur in the depressed phase
80%
Percentage of patients with bipolar who have a recurrence in the year following a mood episode
50%
Type of bipolar where patients experience more depressive symptoms
Bipolar II
Biggest predictor of relapse for patients with bipolar
Residual symptoms
Index mood disorder in bipolar that leads to patients spending less time unwell
Mania
Term for antidepressant induced mania
Switch
Term for when antidepressants over time increase the long-term frequency of manic episodes
Mood destabilisation
Percentage of patients with bipolar who show antidepressant switch
20-40%
Risk factors for antidepressant switch in patients with bipolar
Previous antidepressant induced mania
Bipolar family history
Exposure to multiple antidepressants
Initial illness beginning in adolescence or young adulthood
Features of bipolar depression compared to unipolar depression
Bipolar depression shows less anxiety, fewer physical complaints, hypersomnia, more withdrawal, and more atypical symptoms
Definition of rapid cycling bipolar disorder
4 or more episodes within a year
Definition of ultra-rapid cycling bipolar disorder
4 or more episodes within a month
Definition of ultra-ultra-rapid cycling bipolar disorder
Switches within one day on four or more days per week
Percentage of patients with bipolar who are rapid cyclers
20%
Percentage of patients with rapid cycling bipolar disorder who are women
80%
Clinical features of rapid cycling compared to standard bipolar disorder
Earlier onset of illness in rapid cycling
More severe depression and mania in rapid cycling
Lower global functioning in rapid cycling
Risk factors for rapid cycling
Hypothyroidism
Poor response to lithium
Younger age of onset
Substance misuse
Most commonly prescribed medications associated with secondary mania
Corticosteroids
L-dopa
Number of days of symptoms required for a diagnosis of mania
7 days
Number of days of symptoms required for a diagnosis of hypomania
4 days
First line treatment in a first episode of mania
Antipsychotics - haloperidol, olanzapine, quetiapine, or risperidone
Treatment for a first episode of mania if the patient is on antidepressants
Consider stopping the antidepressant
Treat with an antipsychotic regardless of whether the antidepressant is stopped
First line treatment in an episode of mania where the patient is known to have bipolar and is already on a mood stabiliser
Increase the dose of the mood stabiliser
Treatment options in an episode of mania where the patient is known to have bipolar
Increase the dose of the mood stabiliser (first line)
Augment the mood stabiliser with an antipsychotic if taking lithium or valproate
If already taking an antipsychotic - augment with lithium or valproate
ECT
When to consider ECT in an episode of mania where the patient is known to have bipolar
Severely unwell patients
Treatment-resistant mania
Patient preference
Pregnant women
Psychotropic with the highest risk of hyponatraemia
Carbamazepine
First line treatments for bipolar depression
Psychological intervention
Fluoxetine combined with lithium
Quetiapine monotherapy
Second line medication for bipolar depression
Lamotrigine - can be used in combination or as monotherapy
NICE recommendations for when to use long term maintenance management for patients with bipolar
After a manic episode with significant risk or adverse consequences
Bipolar I when there have been two manic episodes
Bipolar II when there is significant functional impairment or risk
First line treatment for long term maintenance of bipolar disorder
Lithium
Benefits of lithium therapy in bipolar disorder
Prevents manic and depressive relapse - more effective in preventing mania
Reduces risk of suicide
Mood stabilisers which are more effective against manic than depressive episodes
Lithium
Valproate
Mood stabilisers which are more effective against depressive than manic episodes
Lamotrigine
Antipsychotics which can be used as maintenance therapy in bipolar disorder
Olanzapine
Quetiapine
Treatment options for mixed episodes in bipolar disorder
Should be treated as manic episodes
Mood stabiliser with the best evidence for mixed episodes
Valproate
Treatment for rapid cycling bipolar
Treat hypothyroidism and substance misuse if present
Discontinue antidepressants
Consider lithium, valproate, and lamotrigine
Number of years maintenance therapy should be continued for patients with bipolar disorder
At least 2 years
At least 5 years if the patient has risk factors for relapse
Antidepressant class with the highest risk of causing a switch
TCAs
Length of time antidepressants should be continued in bipolar depression
3-4 months
Triad of symptoms seen in antidepressant associated chronic irritable dysphoria in patients with bipolar disorder
Irritability
Middle of the night insomnia
Dysphoria
Antiepileptics with no use for treatment of mania
Vigabatrin
Topiramate
Phenytoin
Side effects of vigabatrin
Psychosis
Visual field defects
Visual side effects of topiramate
Diplopia
Acute myopia
Angle closure glaucoma
Benzodiazepine with the best evidence base for use in acute mania
Clonazepam
Most effective medication to reduce suicidality in patients with bipolar disorder
Lithium
Percentage of patients diagnosed with depression who convert to a diagnosis of bipolar each year
0.3-4%
Percentage of patients diagnosed with depression who convert to a diagnosis of bipolar within five years
8-14%
Best intervention for acute lithium toxicity with neurological features
Haemodialysis
Percentage of middle aged women taking lithium who experience hypothyroidism
20%
Percentage of people taking lithium who develop a tremor
25%
Frequency of dosing of lithium with the highest risk of polyuria
Twice daily dosing
Parathyroid issue rarely caused by lithium
Hyperparathyroidism
Evidence based psychotherapies for bipolar disorder
Family therapy
CBT
Psychoeducation
Interpersonal and social rhythms therapy
Mood stabiliser which interferes with oral contraceptives
Carbamazepine
Male:female ratio for bipolar I
1:1
Male:female ratio for bipolar II
1:1.3
Mood stabiliser most likely to cause thrombocytopaenia
Sodium valproate
Initial treatment options for maintenance therapy in bipolar disorder
Lithium
Valproate
Olanzapine
Quetiapine
First line mood stabiliser in hepatic impairment
Lithium
Mood stabilisers contraindicated in severe hepatic impairment
Sodium valproate
Gabapentin
Mood stabiliser relatively contraindicated in renal impairment
Lithium
Interaction between aminophylline and lithium
Lithium levels reduced
Mood stabiliser which can exacerbate psoriasis
Lithium
Sex more likely to experience mixed affective states in bipolar disorder
Women
Percentage of patients who have had a single manic episode who go on to have recurrent mood episodes
90%
Features of cyclothymic disorder
Multiple mood episodes over a period of two years
Both high and low moods
Episodes do not meet criteria for either depression or hypomania/mania
Length of time a manic episode needs to last for
One week
Any duration if hospitalisation is required
Length of time a hypomanic episode needs to last for
4 days
Number of additional symptoms required for a diagnosis of a manic episode as well as mood
3
4 if the mood is irritable rather than elevated
Additional symptoms which suggest an episode of mania
Grandiosity
Flight of ideas
Decreased sleep
Increased talking
Distractability
Increase in goal directed activity
Psychomotor agitation
Involvement in activities with potential for painful consequences
Interaction between sodium valproate and lamotrigine
Valproate increases lamotrigine levels >2x
Interaction between oral contraceptive and lamotrigine
Oral contraceptive decreases lamotrigine levels by half
Rate of serious rash related to lamotrigine therapy
0.08-0.13%
Length of time over which lithium therapy should be stopped
One month
Klerman’s bipolar subtype I
Mania with depression
Klerman’s bipolar subtype II
Hypomania with depression
Klerman’s bipolar subtype III
Cyclothymia
Klerman’s bipolar subtype IV
Antidepressant induced mania or hypomania
Klerman’s bipolar subtype V
Depression in a patient with a family history of bipolar disorder
Klerman’s bipolar subtype VI
Mania without depression
Frequency lithium levels should be monitored in a healthy patient established and stable on therapy
Every 6 months
Patient groups who should have lithium levels monitored every three months
Older patients
Impaired renal function
Impaired thyroid function
Raised calcium levels
Poor control or adherence
Last level >0.8
Taking NSAIDs
Frequency with which TFTs should be checked for a patient on lithium
Six monthly
Uses for lithium
Acute treatment in mania
Prophylactic treatment in bipolar disorder
Augmentation in depression
Aggressive and self mutilating behaviour
Steroid induced psychosis
To raise WCC in patients on clozapine
Investigations which should be done before lithium is commenced
U&Es
ECG
TFTs
FBC
BMI
Timing of lithium medication preferred
Once daily at night
Optimum level for lithium when used in acute mania for a young, healthy patient
0.8-1mmol/L
Treatment best tolerated in patients with acute mania
Olanzapine
Eye sign in severe lithium toxicity
Downbeat nystagmus
ECG changes seen in lithium toxicity
T wave flattening
Prolonged QTc
Mood stabiliser which causes bleeding gums
Carbamazepine
Interactions between lithium and ECT
Increased risk of delirium
Prolonged seizures
Toxic lithium levels
Prolonged neuromuscular blockade
First line treatment for long term maintenance of bipolar disorder in renal impairment
Sodium valproate
Length of time a driving license should be suspended after one episode of mania
3 months
Length of time a driving license should be suspended after an episode of mania, if the patient has had 4 or more episodes in the past year
6 months
Anti epileptic drug which can lower transaminases
Vigabtrin
Condition most associated with reverse neurovegetative symptoms
Bipolar depression
Examples of reverse neurovegetative symptoms
Hyperphagia
Hypersomnia